Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin

Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in human cancer and contributes to resistance to antitumor therapy. Inhibition of key signaling proteins in this pathway therefore represents an attractive targeting strategy for cancer therapy. Here, we show that SH...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Chengying, Chen, Xiangling, Zheng, Mingyue, Liu, Xiaohong, Wang, Hongbin, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746119/
https://www.ncbi.nlm.nih.gov/pubmed/29296217
http://dx.doi.org/10.18632/oncotarget.22439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746119/
https://www.ncbi.nlm.nih.gov/pubmed/29296217
http://dx.doi.org/10.18632/oncotarget.22439

Ejemplares similares